10,500 Shares in Scholar Rock Holding Corporation $SRRK Bought by SBI Okasan Asset Management Co.Ltd.

SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 10,500 shares of the company’s stock, valued at approximately $474,000.

Several other institutional investors have also recently made changes to their positions in SRRK. AQR Capital Management LLC raised its holdings in shares of Scholar Rock by 609.3% during the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after purchasing an additional 49,217 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Scholar Rock by 12.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after purchasing an additional 5,831 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after purchasing an additional 54,555 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after purchasing an additional 34,594 shares during the last quarter. Finally, Strs Ohio purchased a new position in shares of Scholar Rock during the first quarter worth $77,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SRRK. JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Tuesday, April 21st. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday, March 3rd. Barclays lifted their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, BMO Capital Markets lifted their price objective on shares of Scholar Rock from $50.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, March 4th. Five equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $56.00.

Scholar Rock Stock Performance

SRRK opened at $49.30 on Friday. The firm has a market capitalization of $5.91 billion, a PE ratio of -13.73 and a beta of 0.70. Scholar Rock Holding Corporation has a twelve month low of $27.07 and a twelve month high of $52.19. The firm’s 50-day moving average price is $47.91 and its 200 day moving average price is $45.15. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period in the previous year, the business posted ($0.67) EPS. As a group, sell-side analysts expect that Scholar Rock Holding Corporation will post -3.18 EPS for the current fiscal year.

Insider Buying and Selling at Scholar Rock

In other news, COO Keith Woods sold 10,220 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $506,605.40. Following the completion of the sale, the chief operating officer owned 620,055 shares in the company, valued at $30,736,126.35. This trade represents a 1.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David Hallal sold 30,615 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $1,517,585.55. Following the sale, the chief executive officer owned 1,639,034 shares of the company’s stock, valued at $81,246,915.38. This represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 63,491 shares of company stock valued at $3,147,249. Insiders own 13.30% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).